Albany Molecular Research Inc. has opened its new U.-based integrated drug discovery center in Buffalo, New York. Located on the Buffalo Niagara Medical Campus and part of the larger commitment by the State of New York with SUNY Polytechnic Institute. The center in intended to increase translation to the clinic by leveraging expertise in biology, high-throughput screening (HTS), medicinal chemistry, and pharmacology integrated within a single site.

AMRI’s HTS capabilities include compound and sample management, conventional and next-generation HTS and access to equipment and readout instruments. “The ultimate aim of this site is to provide a suite of discovery services, from assay development and HTS to medicinal chemistry and in vitro pharmacology, that will reduce data cycle times in order to improve the value of our customers’ discovery programs, as well as offer ease-of-communication with project teams and functional groups,” said Rory Curtis, vice president, discovery biology and pharmacology, and site head of AMRI Buffalo,” in a company release.

AMRI has partnered with New York State as a founding member of the Buffalo Medical Innovation and Commercialization Hub (BMIC). This hub combines the expertise of academic and industrial partners, creating opportunities for new collaborations to develop new approaches. AMRI’s core competencies include reagent generation; assay development; hit-finding HTS; fast-track, hit-to-lead and lead optimization medicinal chemistry; in vitro pharmacology; in vitro absorption, distribution, metabolism, excretion, toxicity (ADMET); and antibody drug conjugate optimization.

Source: AMRI